Aripiprazole: Does Partial Dopaminergic Agonism Translate into Clinical Benefits?

Ban TA . Pharmacotherapy of mental illness — a historical analysis. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 709–27.

Kane J , Honigfeld G , Singer J , Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96.

Meltzer HY , Alphs L , Green AI , Altamura AC , Anand R , Bertodi A , et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82–91.

Brown CS , Markowitz JS , Moore TR , Parker NG . Atypical antipsychotics: part II: adverse effects, drug interactions, and costs. Ann Pharmacother 1999; 33: 210–7.

Meltzer HY , Matsubara S , Lee JC . Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. J Pharmacol Exp Ther 1989; 251: 238–46.

Kapur S , Seeman P. Does fast dissociation from the dopamine D₂ receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360–9.

Ozdemir V , Fourie J , Ozdener F. Aripiprazole (Otsuka Pharmaceutical Co.). Curr Opin Invest Drugs 2002; 3: 113–20.

Tamminga CA . Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002; 109: 411–20.

Burris KD , Molski TF , Xu C , Ryan E , Tottori K , Kikuchi T , et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D₂ receptors. J Pharmacol Exp Ther 2002; 302: 381–9.

Stahl SM . Essential psychopharmacology of antipsychotics and mood stabilizers. New York: Cambridge University Press, 2002.

Stahl SM . Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: “Goldilocks” actions at dopamine receptors. J Clin Psychiatry 2001; 62: 841–2.

Stahl SM . Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001; 62: 923–4.

Kane JM , Carson WH , Saha AR , McQuade RD , Ingenito GG , Zimbroff DL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–71.

Saha AR , Carson WH , Ali MW , Dunbar GC , Ingenito G . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder (abstract). WJ Biol Psychiatry 2002; 2 (suppl 1): S305.

Daniel DG , Saha AR , Ingenito G , Carson WH , Dunbar G . Aripiprazole, a novel antipsychotic: overview of a Phase II study result (abstract). Int J Neuropsychopharmacol 2000; 3 (suppl 1): S157.

Petrias JM , McQuade RD , Casey DE , Saha A , Ali MW , Jody DN , et al. Switch to aripiprazole monotherapy (poster). Presented at: The 2002 Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, New Mexico, October 20–23, 2002.

Kern RS , Cornblatt B , Carson WH , Dunbar GC , Ali M , Ingenito G , et al. An open-label comparison of the neurocognitive effects of aripiprazole vs. olanzapine in patients with stable psychosis (abstract). Schizophrenia Res 2001; 49 (suppl 1–2): S234.

Mallinkaarjun S , Salazar DE , Bramer SL . The pharmacokinetics, tolerability and safety of aripiprazole following single and multiple oral dose administration (abstract). Int J Neuropsychopharmacol 2000; 3 (suppl 1): S123.